New FDA fast track status for Medicinova Inc.'s phase II nonalcoholic steatohepatitis (NASH) drug MN-001 (tipelukast) invigorated the company's U.S.-listed shares (NASDAQ:MNOV), pushing them 41.3 percent higher to $4.96 in heavy trading Thursday as investors warmed to the company's chances for gaining FDA approval to treat the chronic liver condition, for which no drug is currently approved.